Immunomodulatory effects of CD38-targeting antibodies
- 1 July 2018
- journal article
- research article
- Published by Elsevier BV in Immunology Letters
- Vol. 199, 16-22
- https://doi.org/10.1016/j.imlet.2018.04.005
Abstract
No abstract availableKeywords
Funding Information
- Janssen Pharmaceuticals
- Amgen
- Celgene
- Novartis
- BMS
This publication has 69 references indexed in Scilit:
- Lenalidomide for the treatment of relapsed and refractory multiple myelomaCancer Management and Research, 2012
- Multiple MyelomaNew England Journal of Medicine, 2011
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and PathologyPhysiological Reviews, 2008
- CD38/CD19: a lipid raft–dependent signaling complex in human B cellsBlood, 2007
- Methodologic advancements in the study of airway smooth muscleJournal of Allergy and Clinical Immunology, 2004
- A Single Protein Immunologically Identified as CD38 Displays NAD+ Glycohydrolase, ADP-Ribosyl Cyclase and Cyclic ADP-Ribose Hydrolase Activities at the Outer Surface of Human ErythrocytesBiochemical and Biophysical Research Communications, 1993
- Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10Cell, 1981